Lv4
585 积分 2021-05-10 加入
A disease-modifying approach to the treatment of IgA nephropathy targeting mucosal IgA synthesis and beyond
2小时前
待确认
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
5天前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
4个月前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
4个月前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
4个月前
已完结
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
4个月前
已完结
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
4个月前
已完结
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
4个月前
已完结
皖公网安备34019202002308
